Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of its new Teen and Young Adult (TYA) Program, TYA @ MSK, which will offer special services to MSK’s TYA population. In tandem, MSK officially opened The Lounge, a space designed especially for this unique age group that was made possible by a $1 million donation from Teen Cancer America. The nonprofit organization, co-founded by Roger Daltrey and Pete Townshend of The Who, partners with hospitals throughout the United States to develop specialized facilities for teens and young adults with cancer.
The Lehigh Valley Health Network (LVHN) Cancer Institute is now a formal member of the Memorial Sloan Kettering (MSK) Cancer Alliance, a transformative initiative to improve the quality of care and outcomes for people with cancer in community healthcare settings. Representatives of both organizations made the announcement today at Lehigh Valley Hospital–Cedar Crest following an intensive six-month collaborative review process.
Memorial Sloan Kettering Cancer Center (MSK) announced today that it has received Magnet® recognition, the nation’s highest honor for excellence in nursing. Granted by the American Nurses Credentialing Center (ANCC), Magnet® recognition is the most prestigious distinction a healthcare organization can receive for nursing excellence and quality patient outcomes. Only about 7 percent of hospitals nationally carry this prestigious designation.
Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and the highest caliber of cancer care. Leaders from both institutions have confirmed the first step in announcing their recently signed agreement for Miami Cancer Institute to join the Memorial Sloan Kettering Cancer Alliance.
In response to low national vaccination rates for the human papillomavirus (HPV), Memorial Sloan Kettering Cancer Center (MSK) has joined with the 68 other National Cancer Institute (NCI)–designated cancer centers in issuing a statement urging for increased HPV vaccination for the prevention of cancer. These institutions collectively recognize insufficient vaccination as a public health threat and call upon the nation’s physicians, parents, and young adults to take advantage of this rare opportunity to prevent many types of cancer.
A major transformation is beginning in cancer surgery that will enable patients to go home within a day of undergoing a significant operation. The new Josie Robertson Surgery Center (JRSC), opened by Memorial Sloan Kettering, exemplifies that transformation: a patient-focused facility that leverages technology and highly trained clinical teams to provide optimal care.
Information gleaned from a liquid biopsy may help predict how individual women with advanced breast cancer will respond to certain therapies as well as reveal genetic mutations that can impact prognosis, according to two new studies led by Memorial Sloan Kettering Cancer Center (MSK) Physician-in-Chief José Baselga and physician-scientist Sarat Chandarlapaty. The studies were presented this week at the San Antonio Breast Cancer Symposium.
Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.
Philip W. Kantoff, MD, has been named the new Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). An accomplished leader, physician, researcher, and mentor, Dr. Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School (HMS) since 1987 in a variety of capacities. He formally assumes his new position as George J. Bosl, MD, steps down from his role after 18 years.
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.